--- title: "Canon Stock And 2 Japanese Dividend Shares Backed By Steady Cash Flow" type: "News" locale: "en" url: "https://longbridge.com/en/news/296431213.md" description: "The article highlights three Japanese dividend stocks—Canon, Tokio Marine Holdings, and Daiichi Sankyo—as attractive options for income-focused investors seeking high yields backed by steady cash flow. Canon benefits from recurring revenue in its printing segment; Tokio Marine offers a 3.38% yield supported by underwriting and investment income despite compressed margins; and Daiichi Sankyo leverages oncology drugs to fund dividends. These companies are selected from a screener targeting firms with strong dividend profiles." datetime: "2026-08-20T03:47:57.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296431213.md) - [en](https://longbridge.com/en/news/296431213.md) - [zh-HK](https://longbridge.com/zh-HK/news/296431213.md) generator: "portal-rs" --- # Canon Stock And 2 Japanese Dividend Shares Backed By Steady Cash Flow With US 10 year Treasury yields hovering near recent highs, income focused investors are once again comparing bond coupons with equity income. Cash rates and government bonds offer clearer reference points for yield hunters, yet they do not offer the potential for dividend growth. This article looks at three dividend powerhouses from our 5%+ Dividend Powerhouses screener that offer high yield, coverage and consistency. The three stocks below are just a sample from this idea. The full screen surfaces 474 more companies with similarly compelling dividend profiles that are not covered here. Head straight into the Dividend Powerhouses (3%+ Yield) screener to identify, compare, and analyze the highest conviction opportunities for your own income portfolio. ## Canon (TSE:7751) **Overview:** Canon is a diversified Japanese technology company best known for its printers and cameras. It has a large Printing Business Unit that sells office and production printers plus consumables that generate recurring cash flow to support its dividend profile. Around this core, Canon also produces medical imaging systems, semiconductor and display equipment, and a wide range of professional imaging products. **Operations:** Canon generates most of its revenue from the Printing segment at ¥2,512.7b. This is followed by Imaging at ¥1,134.8b, Medical at ¥578.8b, Industrial at ¥346.5b, and other activities at ¥233.3b. **Market Cap:** ¥3.8t Income investors may find Canon interesting because its mature Printing Business Unit produces recurring revenue from office printers and consumables, which helps underpin a high, covered dividend while the rest of the group adds additional earnings streams. Recent H1 2026 results showed higher sales and net income, which reflects steady cash generation. Canon also completed a sizeable share buyback that returned more capital to shareholders. However, the dividend record is not perfectly smooth and the company is more diversified than a pure printing cash cow, so payout stability still deserves close attention. Canon currently appears to trade below some estimates of fair value, which could be relevant for investors who focus on cash flow and valuation. Canon’s steady cash generation and recent buyback may be masking a more interesting valuation story. View the full DCF valuation analysis for Canon to see what the current pricing might be missing. 7751 Discounted Cash Flow as at Aug 2026 ### Build your own dividend and cash flow shortlist Canon and the other two dividend stocks in this article all came from a single Simply Wall St screen, but your best ideas will often come from filters tuned to your own approach. Use our flexible Screener to combine dividend strength, valuation, growth and risk filters, or start with any of our curated Investing Ideas. ## Tokio Marine Holdings (TSE:8766) **Overview:** Tokio Marine Holdings is a large Japanese insurance group that sells a wide range of non life and life insurance products globally, from personal and commercial cover to specialist reinsurance and risk solutions. Its attraction for dividend focused investors lies in its mature, cash generative underwriting and investment income, which support regular, well covered dividend payouts rather than relying on more volatile growth stories. **Operations:** Tokio Marine Holdings generates most of its revenue from Overseas Insurance Business at ¥5.4t and Domestic Property and Casualty Insurance at ¥3.2t, with smaller contributions from Domestic Life Insurance at ¥445b and Solution and Other Business at ¥328b. **Market Cap:** ¥13.8t Tokio Marine provides exposure to a large scale insurer with a 3.38% dividend yield backed by diversified underwriting and investment income, plus active buybacks that support earnings per share. The group is working on becoming leaner through its Re New initiative in Japan and by selling cross shareholdings to recycle capital into higher return areas, while still aiming to keep dividends well covered. At the same time, profit margins have compressed from 15.9% to 6.5% and return on equity remains modest, so investors may want to monitor how profit quality and capital allocation evolve. The push into solution businesses such as disaster resilience and carbon related insurance presents additional potential cash flow sources that are not yet fully reflected in the headline yield story. Tokio Marine’s compressed margins and modest return on equity sit beside a 3.38% yield and active buybacks that the headline story does not fully explain. Get the full picture in the 3 key rewards and 1 important warning sign TSE:8766 Revenue & Expenses Breakdown as at Aug 2026 ## Daiichi Sankyo Company (TSE:4568) **Overview:** Daiichi Sankyo Company is a global pharmaceutical company focused on oncology and specialty medicines, with key drugs such as Enhertu, Datroway and Vanflyta treating various cancers and supporting cash flows that can fund its dividend. The company also sells treatments for cardiovascular disease, diabetes, migraine, osteoporosis, epilepsy and vaccines, which broaden its revenue base beyond oncology. **Operations:** Daiichi Sankyo generates all of its ¥2,223.2b in revenue from its Pharmaceutical Operation segment. **Market Cap:** ¥5.0t Income-focused investors may consider Daiichi Sankyo Company because its oncology franchise, led by Enhertu and Datroway, is being supported by new approvals and partnerships that can expand recurring cash flows. Recent trial results and regulatory progress in breast, lung and triple negative breast cancer, plus deals such as the China partnership for Vanflyta, provide additional support, while a 3.66% dividend yield offers an immediate income stream. The dividend is not well covered by free cash flow and profit margins have been under pressure, so payout resilience is not comparable to long-established dividend payers. The balance between that yield, the oncology portfolio and the risks from drug concentration and pricing policy is a key consideration for investors evaluating Daiichi Sankyo. Enhertu, Datroway and Vanflyta hint at a much bigger story for Daiichi Sankyo Company, where oncology cash flows and a 3.66% yield intersect with fragile coverage. Get the full analysis report for Daiichi Sankyo Company TSE:4568 Revenue & Expenses Breakdown as at Aug 2026 ## Seeking Fresh Alternatives For Your Income? Markets move fast and new dividend stories can gain breakout momentum before most investors even notice. Keep your edge while it matters and get in early. - Consider resilient cash generators that may be less widely watched by screening companies with the list of solid balance sheet and fundamentals (41 results). - Follow early momentum in promising miners by tracking curated producers through the 30 elite gold producer stocks. - Identify under the radar opportunities with potential for re rating by filtering curated stocks via the 70 high quality undiscovered gems. *This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.* ### **New:** Manage All Your Stock Portfolios in One Place We've created the **ultimate portfolio companion** for stock investors, **and it's free.** • Connect an unlimited number of Portfolios and see your total in one currency • Be alerted to new Warning Signs or Risks via email or mobile • Track the Fair Value of your stocks Try a Demo Portfolio for Free ### Related Stocks - [8766.JP](https://longbridge.com/en/quote/8766.JP.md) - [4568.JP](https://longbridge.com/en/quote/4568.JP.md) - [7751.JP](https://longbridge.com/en/quote/7751.JP.md) - [CAJPY.US](https://longbridge.com/en/quote/CAJPY.US.md) - [DSNKY.US](https://longbridge.com/en/quote/DSNKY.US.md) ## Related News & Research - [2 dividend stocks that are no-brainer buys in August](https://longbridge.com/en/news/296183845.md) - [YieldMax XOM Option Income Strategy ETF declares $0.0895 dividend](https://longbridge.com/en/news/296397963.md) - [YieldMax INTC Option Income Strategy ETF declares $0.642 dividend](https://longbridge.com/en/news/296365803.md) - [YieldMax BRK.B Option Income Strategy ETF declares $0.1399 dividend](https://longbridge.com/en/news/296383218.md) - [YieldMax META Option Income Strategy ETF declares $0.0466 dividend](https://longbridge.com/en/news/296363698.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**